Abstract

BackgroundFebrile children seen in malaria hypo-endemic settings, such as the Greater Accra region (GAR) of Ghana are more likely to be suffering from a non-malarial febrile illness compared to those seen in hyper-endemic settings. The need for prescribers to rely on malaria test results to guide treatment practices in the GAR is even greater. This study was designed to investigate the factors associated with inappropriate artemisinin-based combination therapy (ACT) prescription.MethodsA survey was conducted in six health facilities in the region in 2015. Treatment practices for febrile outpatient department (OPD) patients were obtained from their records. Prescribers were interviewed and availability of malaria commodities were assessed. The primary outcome was the proportion of patients prescribed ACT inappropriately. Independent variables included patient age and access to care, prescriber factors (professional category, work experience, access to guidelines, exposure to training). Data were analysed using Stata at 95% CI (α-value of 0.05). Frequencies and means were used to describe the characteristics of patients and prescribers. To identify the predictors of inappropriate ACT prescription, regression analyses were performed accounting for clustering.ResultsOverall, 2519 febrile OPD records were analysed; 45.6% (n = 1149) were younger than 5 years. Only 40.0% of patients were tested. The proportion of patients who were prescribed ACT inappropriately was 76.4% (n = 791 of 1036). Of these 791 patients, 141 (17.8%) were prescribed anti-malarial injections. Patients seen in facilities with rapid diagnostic tests (RDT) in stock were less likely to be prescribed ACT inappropriately, (AOR: 0.04, 95% CI 0.01–0.14, p < 0.001) compared to those seen in facilities with RDT stock-outs. Prescribers who had been trained on malaria case management within the past year were 4 times more likely to prescribe ACT inappropriately compared to those who had not been trained (AOR: 4.1; 95% CI (1.5–11.6); p < 0.01). Patients seen by prescribers who had been supervised were 8 times more likely to be prescribed ACT inappropriately.ConclusionInappropriate ACT prescription to OPD febrile cases was high. Training and supervision of health workers appears not to be yielding the desired outcomes. Further research is needed to understand this observation.

Highlights

  • Febrile children seen in malaria hypo-endemic settings, such as the Greater Accra region (GAR) of Ghana are more likely to be suffering from a non-malarial febrile illness compared to those seen in hyper-endemic settings

  • Patients who test positive for malaria are expected to be prescribed any of three recommended oral artemisinin-based combination therapy (ACT), which are artesunate–amodiaquine (ASAQ), artemether–lumefantrine (AL) or dihydroartemisinin– piperaquine (DHAP) [8], and anti-malarial treatment must generally be withheld from febrile patients who test negative for malaria parasites

  • 57.6% of these patients were registrants of the National Health Insurance Scheme (NHIS) or other health insurance schemes. These patients were seen by 82 prescribers, whose mean age was 32.2 years with a standard deviation (SD) of ± 1.28, and the distribution showed that 80.2% of them were below the age of 40 years

Read more

Summary

Introduction

Febrile children seen in malaria hypo-endemic settings, such as the Greater Accra region (GAR) of Ghana are more likely to be suffering from a non-malarial febrile illness compared to those seen in hyper-endemic settings. Malaria remains a significant contributor of morbidity in Ghana. It was responsible for between 30.9 and 44.0% of all outpatient department (OPD) cases from 2009 to 2016 [1,2,3,4,5,6], and between January and March 2017, 2.3 million suspected malaria cases, which required treatment [7], were seen in OPDs across the country. Patients who test positive for malaria are expected to be prescribed any of three recommended oral artemisinin-based combination therapy (ACT), which are artesunate–amodiaquine (ASAQ), artemether–lumefantrine (AL) or dihydroartemisinin– piperaquine (DHAP) [8], and anti-malarial treatment must generally be withheld from febrile patients who test negative for malaria parasites

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call